ATTN: Medical Health Officers and Branch Offices
Public Health Nursing Administrators and Assistant Administrators
Holders of Communicable Disease Control Manuals

Re: Update to Communicable Disease Control Manual, Chapter 2: Immunization,
Part 4 – Biological Products & Appendix E – Management of Biologicals

Part 4 – Biological Products

COVID-19 Vaccines

COVID-19 Vaccine Comirnaty® (Pfizer-BioNTech) Adult/Adolescent (Gray Vial Cap)

- A new product page has been developed for the Comirnaty® (Pfizer-BioNTech) Adult/Adolescent vaccine supplied with a gray vial cap and gray border around the vial.
- This presentation does not require dilution and has improved stability at refrigerated temperatures of +2°C to +8°C (i.e., 10 weeks) compared to the product with the purple vial cap.

Please add new page numbers: 1-6 dated July 29, 2022

COVID-19 Vaccine Comirnaty® (Pfizer-BioNTech) Adult/Adolescent (Purple Vial Cap)

- The vial cap colour has been added to the title of the product page to differentiate this product from the other Pfizer COVID-19 vaccine presentations.
- Content for low dead-volume syringes and/or needles has been streamlined under Administration.
- Content related to reported rates of myocarditis under Adverse Events has been updated.

Please remove page numbers: 1-6 dated July 8, 2022
Please add new page numbers: 1-6 dated July 29, 2022
COVID-19 Vaccine Comirnaty® (Pfizer-BioNTech) Pediatric (Orange Vial Cap)

- The vial cap colour has been added to the title of the product page to differentiate this product from the other Pfizer COVID-19 vaccine presentations.
- Content under Doses and Schedule for CEV clients has been revised from 6-11 years to 5-11 years to allow for age-appropriate consideration for Moderna COVID-19 vaccine.
- Content for low dead-volume syringes and/or needles has been streamlined under Administration.
- Content related to reported rates of myocarditis under Adverse Events has been updated.

Please remove page numbers: 1-5 dated May 5, 2022
Please add new page numbers: 1-5 dated July 29, 2022

Please also remove the Title Page and Table of Contents for Part 4 – Biological Products dated July 2022 and replace with the enclosed updated Title Page and Table of Contents dated July 29, 2022.

The new COVID-19 mRNA Vaccine Comparison Table has been developed to highlight the identifiers for each of the COVID-19 mRNA vaccine products supplied in BC. This resource has been posted on the COVID-19 vaccination toolkit for health professionals under General COVID-19 vaccine information.

Appendix E – Management of Biologicals

Guidance for Receiving and Handling the Pfizer-BioNTech COVID-19 mRNA Vaccine (including dry ice procedures)

- The content under “Temperature Requirements for Shipping and Storage upon Receipt of the Vaccine” has been extensively revised to include storage and handling information for the 3 different presentations of the Pfizer-BioNTech COVID-19 vaccine.

Please remove page numbers: 1-12 dated August 31, 2021
Please add new page numbers: 1-13 dated July 29, 2022
If you have any questions or concerns, please contact Stephanie Meier, Senior Practice Leader, BCCDC (telephone: 604-707-2577 / email: stephanie.meier@bccdc.ca).

Sincerely,

Monika Naus MD MHSc FRCPC FACPM
Medical Director
Communicable Diseases & Immunization Service
BC Centre for Disease Control

pc:
Provincial Health Officer
Dr. Bonnie Henry

Dr. Reka Gustafson
Vice President, Public Health & Wellness, PHSA & Deputy Provincial Health Officer

Deputy Provincial Health Officer
Dr. Martin Lavoie

BC Ministry of Health, Population & Public Health Division:

Brian Sagar
Senior Director Communicable Disease, Population and Public Health Division

Bernard Achampong
Executive Director, Public Health, Planning and Prevention, Population and Public Health Division